Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials

作者: Jan Magnus Bjordal , Anne Elisabeth Ljunggren , Atle Klovning , Lars Slørdal , None

DOI: 10.1136/BMJ.38273.626655.63

关键词:

摘要: Abstract Objective To estimate the analgesic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclo-oxygenase-2 inhibitors (coxibs), in patients with osteoarthritis knee. Design Systematic review and meta-analysis randomised placebo controlled trials. Studies reviewed 23 trials 10 845 patients, median age 62.5 years. 7807 received adequate doses NSAIDs 3038 placebo. The mean weighted baseline pain score was 64.2 mm on 100 visual analogue scale (VAS), average duration symptoms 8.2 Main outcome measure Change overall intensity pain. Results Methodological quality acceptable, but 13 excluded before randomisation if they did not respond to NSAIDs. One trial provided long term data for that showed no significant effect compared at one four pooled difference all included 10.1 (95% confidence interval 7.4 12.8) or 15.6% better than after 2-13 weeks. results were heterogeneous, size reduction 0.32 (0.24 0.39) a random effects model. In exclude non-responders NSAID treatment homogeneous, an 0.23 (0.15 0.31). Conclusion can reduce short knee slightly placebo, current analysis does support use this condition. As serious adverse are associated oral NSAIDs, only limited be recommended.

参考文章(62)
Geoffrey C Speldewinde, Guy M Bashford, Ian R Davidson, Diagnostic cervical zygapophyseal joint blocks for chronic cervical pain. The Medical Journal of Australia. ,vol. 174, pp. 174- 176 ,(2001) , 10.5694/J.1326-5377.2001.TB143210.X
Ehrich Ew, Kong Sx, Watson Dj, Bolognese Ja, Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. The American Journal of Managed Care. ,vol. 7, pp. 609- ,(2001)
David P Recker, Glenn Eisen, William W Zhao, Alan Kivitz, Terry Bevirt, Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. Journal of Family Practice. ,vol. 51, pp. 530- 537 ,(2002)
Alan J. Kivitz, Maria W. Greenwald, Stanley B. Cohen, Adam B. Polis, Daryl K. Najarian, Mary E. Dixon, Robert A. Moidel, Jerry A. Green, Herbert S. B. Baraf, Richard A. Petruschke, Alan K. Matsumoto, Gregory P. Geba, , , Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial Journal of the American Geriatrics Society. ,vol. 52, pp. 666- 674 ,(2004) , 10.1111/J.1532-5415.2004.52201.X
Jorge Gomez Cerezo, Rubin Lubomirov Hristov, Antonio J. Carcas Sansuán, Juan J. Vázquez Rodríguez, Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits European Journal of Clinical Pharmacology. ,vol. 59, pp. 169- 175 ,(2003) , 10.1007/S00228-003-0579-1
Gerold Stucki, Felix Angst, André Aeschlimann, Beat A Michel, Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. The Journal of Rheumatology. ,vol. 29, pp. 131- 138 ,(2002)
David T. Felson, Timothy McAlindon, Osteoarthritis: New Insights Annals of Internal Medicine. ,vol. 136, pp. 88- 88 ,(2002) , 10.7326/0003-4819-136-1-200201010-00019
Miriam C. J. M. Sturkenboom, Ferdinando Romano, Giorgio Simon, Maria L. Correa-Leite, Marco Villa, Alfredo Nicolosi, Giulio Borgnolo, Gabriele Bianchi-Porro, Salvatore Mannino, The iatrogenic costs of NSAID therapy: a population study. Arthritis & Rheumatism. ,vol. 47, pp. 132- 140 ,(2002) , 10.1002/ART.10268